|
 |
| Established
1999 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| Source: Company documents |
|
|
| Name
: |
Larry W. Papasan |
| Title
: |
Chairman of the Board |
| Since: |
08/2005 |
|
|
|
|
| Name
: |
Samuel E. Lynch |
| Title
: |
President, Chief Executive Officer, Director |
| Since: |
1999 |
|
|
|
|
| Name
: |
Lawrence Bullock |
| Title
: |
Chief Financial Officer |
| Since: |
01/2004 |
|
|
|
|
| Name
: |
Steven N. Hirsch |
| Title
: |
Chief Operating Officer, Executive Vice President - Orthopedics |
| Since: |
07/2005 |
|
|
|
|
| Name
: |
Charles E. Hart |
| Title
: |
Vice President, Chief Scientific Officer |
| Since: |
01/2004 |
|
|
|
|
| Name
: |
Earl Douglas |
| Title
: |
General Counsel |
| Since: |
05/2005 |
|
|
|
|
|
|
|
| |
|
| Earnings
Release Dates : 11th August 2008 , 8th May 2008 , 12th March 2008 , 13th November 2007 |
|
 Audio |
|
|
| |
|
| |
|
| |
|
| |
| Basin Water Soars 40% May 14, 5:25 PM EDT |
|
| |
BioMimetic Therapeutics
The Company’s first drug-device combination product, GEM 21S Growth-factor Enhanced Matrix, received US Food and Drug Administration, or FDA, approval in November 2005 for the treatment of periodontal bone defects and gum tissue recession associated with periodontal disease. GEM 21S combines recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) with a clinically proven synthetic bone matrix, beta-tricalcium phosphate (β-TCP).
|
| More... |
|
|
|
|
|
|
|
|
|
|
| ©
1999-2008 123jump.com. All rights reserved |
|
|
|
|
|
|
|
Warning: Unknown: Your script possibly relies on a session side-effect which existed until PHP 4.2.3. Please be advised that the session extension does not consider global variables as a source of data, unless register_globals is enabled. You can disable this functionality and this warning by setting session.bug_compat_42 or session.bug_compat_warn to off, respectively. in Unknown on line 0
|
